Clinical Trial

Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 14, 2025 (before its estimated May 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this randomized placebo controlled trial is to examine mood disturbance and serum brain derived neurotrophic factor (BDNF) in people (age 18-50) with DASS-21 subscale scores \>9. The main questions it aims to answer are: Does curcumin and EGCG supplementation improve mood disturbance symptomology? Does curcumin and EGCG supplementation increase serum BDNF? Researchers will compare intervention versus placebo. Participants will consume an 8-week supplement of both: * 1,330mg/day curcumin * 350mg/day epigallocatechin gallate (EGCG)
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-07-29; most recent amendment 2025-02-13.
Status change: Not Yet Recruiting → Recruiting 2025-02-13
Trial Details
NCT Number NCT06531863
Lead Sponsor Auburn University
Conditions Mood Disturbance
Enrollment 64 participants
Start Date 2024-09-30
Primary Completion 2025-05-01 (estimated)
Study Completion 2025-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-14